Direct β1/β2 AMPK activation reduces liver steatosis but not fibrosis in a mouse model of non-alcoholic steatohepatitis
K. M. Mather, M. L. Boland, E. L. Rivers, A. Srivastava, M. Schimpl, P. Hemsley, J. Robinson, P. Wan, J. Hansen, J. A. Read, J. L. Trevaskis, D. M. Smith
This study evaluates BI9774, an AMPK activator, in a mouse model of NASH, finding it reduces liver steatosis but not fibrosis and causes cardiac side effects.
bioRxiv · May 30, 2024 · PreprintPharmacology & Toxicology